Estimaciones de analistas de Wall Street para Evogene Ltd. (EVGN): precio objetivo de consenso, recomendaciones de compra/mantener/venta y previsiones de ingresos, BPA y EBITDA para los próximos ejercicios.
Consenso de analistas
| Compra fuerte | 0 |
| Compra | 4 |
| Mantener | 0 |
| Venta | 0 |
| Venta fuerte | 0 |
| Analistas totales | 4 |
| Calificación media (1-5) | 1.00 |
Sorpresas de Resultados Recientes
| Fecha | BPA Real | BPA Estimado | vs Est. |
|---|---|---|---|
| 2026-11-18 | $-0.27 | ||
| 2026-08-18 | $-0.13 | $-0.27 | +51.9% |
| 2026-05-20 | $-0.60 | $-0.27 | -122.2% |
| 2026-03-05 | $-0.61 | $-0.26 | -134.6% |
| 2025-11-20 | $-0.31 | $-0.26 | -19.2% |
| 2025-08-19 | $-0.62 | $-0.63 | +1.6% |
| 2025-05-21 | $-0.38 | $-0.62 | +39.2% |
| 2025-03-06 | $0.06 | $-0.72 | +108.3% |
Ratios de valoración
| Precio / Valor contable | -1.98 |
| EV / EBITDA | 0.19 |
| Rentabilidad por dividendo | 0.00% |
Cuenta de Resultados (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ingresos | $6.5M | $3.4M | $1.7M | $753000 | $1.0M | $930000 | $1.7M | $3.0M | $5.6M | $3.9M |
| Coste de Ventas | $5.6M | $2.8M | $1.5M | $334000 | $574000 | $767000 | $909000 | $1.5M | $2.4M | $4.1M |
| Beneficio Bruto | $901000 | $536000 | $295000 | $419000 | $466000 | $163000 | $766000 | $1.5M | $3.2M | -$241000 |
| I+D | $16.4M | $17.0M | $14.7M | $15.8M | $17.3M | $21.1M | $20.8M | $16.2M | $12.5M | $8.0M |
| Generales y Administrativos | $5.6M | $5.5M | $5.6M | $5.8M | $8.0M | $10.0M | $10.4M | $7.5M | $9.0M | $5.8M |
| Gastos Operativos | $22.0M | $22.5M | $20.3M | $21.6M | $25.3M | $31.1M | $27.7M | $23.7M | $22.0M | $13.8M |
| Beneficio Operativo | -$21.1M | -$21.9M | -$20.0M | -$21.2M | -$24.8M | -$31.0M | -$26.9M | -$22.2M | -$18.8M | -$14.0M |
| EBITDA | -$18.8M | -$18.7M | -$18.8M | -$16.0M | -$23.2M | -$27.9M | -$27.0M | -$20.5M | -$13.4M | -$12.2M |
| Gastos por Intereses | $155000 | $129000 | $141000 | $354000 | $269000 | $403000 | $241000 | $171000 | $124000 | $1.9M |
| Beneficio Antes de Impuestos | -$19.6M | -$20.8M | -$20.8M | -$19.1M | -$26.2M | -$30.4M | -$29.8M | -$21.9M | -$14.8M | -$13.5M |
| Impuestos | $36000 | $11000 | $30000 | $24000 | $32000 | $13000 | $90000 | $19000 | $9000 | $1000 |
| Beneficio Neto | -$19.6M | -$20.8M | -$20.8M | -$18.1M | -$23.4M | -$27.8M | -$26.6M | -$23.9M | -$16.5M | -$8.5M |
| BPA | $-0.77 | $-0.81 | $-0.81 | $-0.70 | $-0.64 | $-0.68 | $-6.46 | $-5.23 | $-2.89 | $-1.08 |
| BPA Diluido | $-0.77 | $-0.81 | $-0.81 | $-0.70 | $-0.64 | $-0.68 | $-6.46 | $-5.23 | $-2.89 | $-1.08 |
| Acciones en Circulación (Diluidas) | $25.4M | $25.7M | $25.8M | $25.8M | $36.6M | $41.0M | $4.1M | $4.6M | $5.7M | $7.9M |
Precio
| Precio | $0.50 |
| Capitalización | $4M |
| Bolsa | NASDAQ |
| País | IL |
Empresas relacionadas: AEON · BOLT · CING · CLRB · COCP · DWTX · GLTO
Explorar sector: Healthcare · Biotechnology
Más secciones de EVGN: Resumen · Financieros · Valoración · Estadísticas · Técnico · Propiedad · Noticias · Eventos
Descubre más: Radar — señales de acciones infravaloradas · Academia de Inversión — aprende a analizar acciones